This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
Diagnosed as local with or without regional recurrence after ≥1 year of radical treatment;
Not suitable for surgery;
Histologic diagnosis of NPC (WHO II/III);
TNM stage rII-IVa (AJCC/UICC 8th);
Treated with anti-tumor Chinese medicine treatment;
Have recurrence with local necrosis;
Have ≥G3 late toxicities, except for skin, subcutaneous tissue or mucosa;
Unexplained fever > 38.5, except for tumor fever;